ArQule, Inc. to Report Second Quarter 2008 Financial Results on Monday, August 11, 2008

ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the second quarter of 2008 in a press release to be issued on Monday, August 11, 2008 at 7:00 a.m. eastern time. The Company will host a conference call and web cast to discuss these results at 9:00 a.m. eastern time on that day. Conference call details     Date: Monday, August 11, 2008 Time: 9:00 a.m. ET Conference Call Numbers Domestic: 866-362-4820 International: 617-597-5345 Participant Passcode: 55588807 Web cast: http://www.arqule.com A replay of the conference call will be available for seven days following the call and can be accessed by dialing toll-free 888-286-8010 and outside the U.S. 617-801-6888. The access code is 60157973. About ArQule ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s clinical-stage products consist of ARQ 197, an inhibitor of the c-Met receptor tyrosine kinase, and ARQ 501, an activator of the cell’s DNA damage response mechanism mediated by the E2F-1 transcription factor. The Company’s most advanced pre-clinical development programs are focused on ARQ 761, a second-generation E2F-1 activator, as well as compounds that inhibit the Eg5 kinesin spindle protein and the B-RAF kinase. ArQule’s discovery efforts are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate), an energy source for cells. For more information, please visit www.arqule.com.